Bioxytran’s Innovative Antiviral Treatment Recognized in Major Grant Submission
BIOXYTRAN, INC. (OTCQB: BIXT), a pioneering clinical-stage biotechnology firm, has recently received significant recognition as the University of Georgia named its antiviral candidate, PHM23, in its submission for the USDA’s $100 million Highly Pathogenic Avian Influenza (HPAI) Poultry Innovation Grand Challenge. This acknowledgment emphasizes PHM23’s potential to provide a groundbreaking solution for combating Bird Flu (H5N1) while showcasing its impressive spectrum of antiviral activity.
Highlighting the Potential of PHM23
The University of Georgia is well-regarded for its leadership in poultry health research. The selection of PHM23 underscores its unique position in the antiviral landscape as a promising therapeutic candidate that can effectively neutralize viral infections. This inclusion in a prestigious grant submission is anticipated to elevate awareness regarding the antiviral properties of Bioxytran’s molecule. By specifically targeting galectins—proteins essential for viral replication—PHM23 has shown potential efficacy against viruses similar to Bird Flu in various in vitro experiments, suggesting its viability as an antiviral option for various viral threats.
CEO Insights on the Recognition
David Platt, CEO of Bioxytran, commented, “This recognition from the University of Georgia is a testament to the transformative potential of complex carbohydrate-based antiviral drugs in addressing one of the most pressing challenges in global agriculture. Being selected for the USDA’s HPAI Poultry Innovation Grand Challenge submission validates our innovative galectin antagonist platform and highlights PHM23’s role in safeguarding animal health and the global food supply. We are excited to collaborate with leading academic institutions to advance this breakthrough therapy.”
Mechanism of Action and Potential Benefits
Bioxytran’s galectin antagonist technology, manifested in PHM23, functions by inhibiting viral spike proteins from attaching to host cells, a mechanism that is consistent across mammals, thus lowering the chances of viral mutations. This promising approach may provide rapid containment of H5N1 outbreaks, potentially eliminating the need for mass culling, which could save billions in losses for the poultry industry.
A Call to Action: Partnering for Progress
The USDA’s HPAI Poultry Innovation Grand Challenge is aimed at limiting the spread of Bird Flu, protecting U.S. poultry farmers, and ensuring food security, with up to $100 million in funding available. Bioxytran is actively pursuing partnerships with academic, industry, and governmental organizations to expedite the development and deployment of PHM23 in response to this critical global demand.
About Bioxytran, Inc.
Bioxytran, Inc. stands at the forefront of developing complex carbohydrate-based therapeutics, focusing on significant unmet medical needs through its core platform technologies. This includes virology, cancer metastasis, and oxygen transport. Alongside ProLectin-M, Bioxytran is developing therapies for pulmonary fibrosis and stroke treatment. Notably, BXT-25 has demonstrated a potential to drastically reduce the time until medical intervention in emergency situations. For more details, visit www.bioxytraninc.com.
Investor Relations Contact
For inquiries, please contact:
Michael Sheikh
Tel: 509-991-0245
Email: mike.sheikh@bioxytraninc.com
This article incorporates the provided content and organizes it into a structured format suitable for a WordPress integration, utilizing appropriate HTML tags for headings and paragraphs.
